Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on DialysisPRNewsWire • 12/17/22
Ardelyx stock rockets on heavy volume after positive FDA panel vote on kidney disease treatmentMarket Watch • 11/17/22
Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on DialysisPRNewsWire • 11/16/22
Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on DialysisPRNewsWire • 11/16/22
National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus LevelsPRNewsWire • 11/04/22
Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business HighlightsPRNewsWire • 11/03/22
Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on DialPRNewsWire • 11/03/22
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in JapanPRNewsWire • 10/31/22